- Home
- ELVN
as 10-22-2025 3:53pm EST
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.2B | IPO Year: | 2020 |
| Target Price: | $41.20 | AVG Volume (30 days): | 399.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.00 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.30 - $29.79 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 20.05% |
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Oct 17 '25 | Sell | $21.33 | 12,500 | $266,653.75 | 902,892 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Oct 7 '25 | Sell | $20.10 | 6,667 | $133,992.70 | 276,641 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Sep 29 '25 | Sell | $20.40 | 3,250 | $66,291.23 | 23,000 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Sep 26 '25 | Sell | $20.25 | 4,000 | $81,005.20 | 927,688 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Sep 26 '25 | Sell | $20.06 | 3,700 | $74,227.55 | 902,892 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Sep 23 '25 | Sell | $20.03 | 1,500 | $30,045.00 | 927,688 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Sep 23 '25 | Sell | $20.03 | 2,800 | $56,084.00 | 902,892 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Sep 19 '25 | Sell | $19.56 | 7,000 | $135,697.35 | 927,688 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Sep 8 '25 | Sell | $20.24 | 6,667 | $134,957.41 | 276,641 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Aug 27 '25 | Sell | $20.63 | 3,250 | $67,038.73 | 23,000 |
Latest Enliven Therapeutics Inc. News
ELVN Breaking Stock News: Dive into ELVN Ticker-Specific Updates for Smart Investing
Zacks
a month ago
Wall Street Analysts Predict a 106.48% Upside in Enliven Therapeutics, Inc. (ELVN): Here's What You Should Know
Zacks
a month ago
Enliven Therapeutics, Inc. (ELVN) Upgraded to Buy: Here's What You Should Know
Insider Monkey
4 months ago
Enliven Therapeutics, Inc. (ELVN) Backed by Goldman Sachs After Strong Trial Data
MT Newswires
4 months ago
Enliven Therapeutics Closes Public Offering
PR Newswire
4 months ago
Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
MT Newswires
4 months ago
Sector Update: Health Care Stocks Slide Late Afternoon
MT Newswires
4 months ago
Top Midday Gainers
MT Newswires
4 months ago
Enliven Therapeutics Prices $200 Million Public Offering of Common Stock, Pre-Funded Warrants
Compare ELVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.